Hepatol Res . Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19

[tetano]

Hepatol Res


. 2020 Jul 30.
doi: 10.1111/hepr.13551. Online ahead of print.
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19


Goki Suda ¹ , Koji Ogawa ¹ , Megumi Kimura ¹ , Osamu Maehara ¹ , Takashi Kitagataya ¹ , Masatsugu Ohara ¹ , Yoshimasa Tokuchi ¹ , Akinori Kubo ¹ , Ren Yamada ¹ , Taku Shigesawa ¹ , Kazuharu Suzuki ¹ , Naoki Kawagishi ¹ , Masato Nakai ¹ , Takuya Sho ¹ , Mitsuteru Natsuizaka ¹ , Kenichi Morikawa ¹ , Naoya Sakamoto ¹



Affiliations

• PMID: 32729953
• DOI: 10.1111/hepr.13551

Abstract

Aim: Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease may increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19.
Methods: We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys? Anti-SARS-CoV-2-assay (Roche Diagnostics).
Results: Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys? were 98% (95% confidence interval (CI), 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys?-Anti-SARS-CoV-2-assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%).
Conclusions: The Elecsys? Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by Elecsys? Anti-SARS-CoV-2-assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020.

Keywords: COVID-19; Elecsys? Anti-SARS-CoV-2 assay; IgG; SARS-CoV-2; liver disease.